The diagnostik value of eosinophil-to-lymphocyte ratio in predicting contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction

Year 2025, Volume: 7 Issue: 2, 120 - 125, 21.03.2025

Orhan Karayiğit , Murat Gök , Ahmet Balun , Alparslan Kurtul

https://doi.org/10.38053/acmj.1605520

Abstract

Aims: Inflammation is considered a major contributor to the development of contrast-induced nephropathy (CIN). The purpose of this study was to assess the effectiveness of eosinophil-to-lymphocyte ratio (ELR) as a predictor of CIN among patients who experienced percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Methods: The study involved 440 patients diagnosed with STEMI who underwent primary PCI. The participants were categorized into two classes based on whether they had CIN or not. ELR was calculated by dividing the eosinophil count by the lymphocyte count.
Results: The group with CIN (+) showed significantly higher ELR levels (0.134±0.063 vs. 0.069±0.037, p<0.001). According to the ROC curve assessment, the best threshold level of ELR to predict CIN development was identified as 0.093, with 75.9% sensitivity and 79.1% specificity (AUC: 0.836; 95% CI: 0.783–0.889; p<0.001). Logistic regression analysis revealed that estimated glomerular filtration rate (eGFR), C-reactive protein, left ventricular ejection fraction, and ELR were independent predictors of CIN.
Conclusion: ELR could be an effective and reliable marker to predict CIN development in individuals with STEMI who undergo primary PCI. Early prediction of CIN risk is critical to provide intensive preventive measures for high-risk patients.

Keywords

Eosinophil-to-lymphocyte ratio, contrast-induced nephropathy, percutaneous coronary intervention, ST-segment elevation myocardial infarction

Ethical Statement

Ethics committee approval was obtained from Yozgat Bozok University Clinical Researches Ethics Committee (Date: 18.12.2024, Decision no:2024-GOKAEK-2415_2024.12.18_251).

Supporting Institution

None

Thanks

None

References

• Elserafy AS, Okasha N, Hegazy T. Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography. Egypt Heart J. 2018;70(2):107-111. doi:10.1016/j.ehj.2017.12.004
• Moro AB, Strauch JGN, Groto AD, Toregeani JF. Creatinine level variation in patients subjected to contrast-enhanced tomography: a meta-analysis. J Vasc Bras. 2021;20:e20200161. doi:10.1590/1677-5449. 200161
• Moitinho MS, Santos ES, Caixeta AM, Belasco AGDS, Barbosa DA, Fonseca CDD. Contrast-induced nephropathy in patients submitted to percutaneous coronary intervention: an integrative review. Rev Bras Enferm. 2020;73(suppl 5):e20200190. doi:10.1590/0034-7167-2020-0190
• Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814-1823. doi:10.1016/S0140-6736(14)60689-9
• Kwasa EA, Vinayak S, Armstrong R. The role of inflammation in contrast-induced nephropathy. Br J Radiol. 2014;87(1041):20130738. doi: 10.1259/bjr.20130738
• Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006;107(2):558-565. doi:10.1182/blood-2005-05-2152
• Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45(10): 1638-1643. doi:10.1016/j.jacc.2005.02.054
• Kounis NG, Soufras GD, Tsigkas G, Hahalis G. White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease. Clin Appl Thromb Hemost. 2015;21(2):139-143. doi:10.1177/1076029614531449
• Vural A, Aydın E. The predictive value of eosinophil indices for major cardiovascular events in patients with acute decompensated HFrEF. Medicina (Kaunas). 2022;58(10):1455. doi:10.3390/medicina58101455
• Vavalle JP, van Diepen S, Clare RM, et al. Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: predictors, clinical and angiographic features, and outcomes. Am Heart J. 2016;173:57-66. doi:10.1016/j.ahj.2015.12.001
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2): 119-177. doi:10.1093/eurheartj/ehx393
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med. 2011;155(6):408]. Ann Intern Med. 2009;150(9):604-612. doi:10. 7326/0003-4819-150-9-200905050-00006
• Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105(5):624-628. doi:10. 1016/j.amjcard.2009.10.044
• Butt K, D'Souza J, Yuan C, et al. Correlation of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Cureus. 2020;12(12):e11879. doi:10.7759/cureus.11879
• Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. 2020;259:118379. doi:10.1016/j.lfs.2020.118379
• Lu Z, Cheng D, Yin J, et al. Antithrombin III protects against contrast-induced nephropathy. EBioMedicine. 2017;17:101-107. doi:10.1016/j.ebiom.2017.02.009
• Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018;2018:9095275. doi:10.1155/2018/9095275
• Colon S, Luan H, Liu Y, Meyer C, Gewin L, Bhave G. Peroxidasin and eosinophil peroxidase, but not myeloperoxidase, contribute to renal fibrosis in the murine unilateral ureteral obstruction model. Am J Physiol Renal Physiol. 2019;316(2):F360-F371. doi:10.1152/ajprenal.00291.2018
• Kielar D, Jones AM, Wang X, et al. Association between elevated blood eosinophils and chronic kidney disease progression: analyses of a large United States electronic health records database. Int J Nephrol Renovasc Dis. 2023;16:269-280. doi:10.2147/IJNRD.S431375
• Widmer A, Linka AZ, Attenhofer Jost CH, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99(1): 25-31. doi:10.1159/000068448
• Núñez J, Miñana G, Bodí V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-3233. doi:10. 2174/092986711796391633
• Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 2018;18(1):1280. doi:10.1186/s12885-018-5131-x
• Yilmaz M, Kayançiçek H, Korkmaz H, et al. A new inflammatory marker: elevated eosinophil-tolymphocyte ratio associated with presence and severity of isolated coronary artery ectasia. Cardiovasc J Afr. 2020;31(5):227-235. doi:10.5830/CVJA-2019-049
• Çetin ZG, Demirtaş B. Understanding the significance of the eosinophil to lymphocyte ratio in individuals with microvascular angina. Bozok Tıp Derg. 2023;13(3):73-80. doi:10.16919/bozoktip.1341814
• Tosu AR, Kalyoncuoğlu M, Biter Hİ, et al. Association of eosinophil-to-lymphocyte ratio with coronary slow-flow phenomenon in patients undergoing coronary angiography. Arch Med Sci Atheroscler Dis. 2022; 7(1):e29-e35. doi:10.5114/amsad.2022.116662